METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS
Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA.
1 . A method of inhibiting a drug resistant bacterial pathogen, comprising:
selecting a drug resistant bacterial pathogen; and
contacting the bacterial pathogen with a composition comprising a therapeutically effective amount of MSM and a therapeutically effective amount of an agent that inhibits the drug-sensitive form of the drug resistant bacterial pathogen, thereby inhibiting a drug resistant bacterial pathogen.
2 . The method of claim 1 , wherein the bacterial pathogen is MRSA.
3 . The method of claim 1 , wherein the agent is a Beta-lactam antibiotic.
4 . The method of claim 3 , wherein the agent comprises penicillin derivatives, cephalosporins, penems, monobactams, carbapenems, Beta-lactamase inhibitors or a combination of two or more thereof.
5 . The method of claim 3 , wherein the agent comprises methicillin, oxacillin or penicillin.
6 . The method of claim 1 , wherein the effective amount of MSM is about 5-20% MSM, about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM.
7 . The method of claim 1 , wherein the effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM.
8 . The method of claim 1 , wherein the effective amount of MSM is about 10-16% MSM.
9 . The method of claim 1 , wherein the bacterial pathogen is on a surface.
10 . The method of claim 1 , wherein the bacterial pathogen is in a subject.
11 . The method of claim 1 , wherein the composition is administered topically.
12 . The method of claim 1 , wherein the composition is administered with an inhalant device.
13 . The method of claim 1 , wherein the bacterial pathogen is contacted with the composition for about 24, 36, 48, 60, 72, 84, 96, 108 or 120 hours.
14 . The method of claim 1 , wherein the composition comprises 0-5% sodium chloride.
15 . A method of sensitizing a drug resistant bacterial pathogen to a drug the bacterial pathogen is resistant to, comprising
selecting a drug resistant bacterial pathogen; and
contacting the bacterial pathogen with a composition comprising a therapeutically effective amount of MSM, thereby sensitizing the drug resistant bacterial pathogen to the drug the bacterial pathogen is resistant to.
16 . The method of claim 15 , wherein the bacterial pathogen is MRSA.
17 . The method of claim 15 , wherein the agent is a Beta-lactam antibiotic.
18 . The method of claim 17 , wherein the agent comprises penicillin derivatives, cephalosporins, penems, monobactams, carbapenems, Beta-lactamase inhibitors or a combination of two or more thereof.
19 . The method of claim 17 , wherein the agent comprises methicillin, oxacillin or penicillin.
20 . The method of claim 15 , wherein the effective amount of MSM is about 5-20% MSM, about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM.
21 . The method of claim 15 , wherein the effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM.
22 . The method of claim 15 , wherein the effective amount of MSM is about 10-16% MSM.
23 . The method of claim 15 , wherein the bacterial pathogen is on a surface.
24 . The method of claim 15 , wherein the bacterial pathogen is in a subject.
25 . The method of claim 15 , wherein the composition is administered topically.
26 . The method of claim 15 , wherein the composition is administered with an inhalant device.
27 . The method of claim 15 , wherein the bacterial pathogen is contacted with the composition for about 24, 36, 48, 60, 72, 84, 96, 108 or 120 hours.
28 . The method of claim 15 , wherein the composition comprises 0-5% sodium chloride.
29 . A method of inhibiting a drug-sensitive bacterial pathogen from developing drug resistance, comprising:
selecting a drug sensitive bacterial pathogen; and
contacting the drug-sensitive bacterial pathogen with a composition comprising a therapeutically effective amount of MSM and a therapeutically effective amount of an agent that inhibits the drug-sensitive bacterial pathogen, thereby inhibiting the drug-sensitive bacterial pathogen from developing drug resistance.
30 . The method of claim 29 , wherein the bacterial pathogen is Staphylococcus aureus.
31 . The method of claim 29 , wherein the agent is a Beta-lactam antibiotic.
32 . The method of claim 31 , wherein the agent comprises penicillin derivatives, cephalosporins, penems, monobactams, carbapenems, Beta-lactamase inhibitors or a combination of two or more thereof.
33 . The method of claim 31 , wherein the agent comprises methicillin, oxacillin or penicillin.
34 . The method of claim 29 , wherein the effective amount of MSM is about 5-20% MSM, about 5-16% MSM, about 5-10% MSM, about 5-8% MSM, about 9-16% MSM or about 10-15% MSM.
35 . The method of claim 29 , wherein the effective amount of MSM is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16% MSM.
36 . The method of claim 29 , wherein the effective amount of MSM is about 10-16% MSM.
37 . The method of claim 29 , wherein the bacterial pathogen is on a surface.
38 . The method of claim 29 , wherein the bacterial pathogen is in a subject.
39 . The method of claim 29 , wherein the composition is administered topically.
40 . The method of claim 29 , wherein the composition is administered with an inhalant device.
41 . The method of claim 29 , wherein the bacterial pathogen is contacted with the composition for about 24, 36, 48, 60, 72, 84, 96, 108 or 120 hours.
42 . The method of claim 29 , wherein the composition comprises 0-5% sodium chloride.